Oestrogen, brain function, and neuropsychiatric disorders

Journal of Neurology Neurosurgery and Psychiatry

Volumn 74, Issue 7, 2003, Pages 837-840

  Cutter, W J ^a   Norbury, R ^a   Murphy, D G M ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN;

ALZHEIMER DISEASE; BRAIN PROTECTION; COGNITION; DEPRESSION; EDITORIAL; ESTROGEN METABOLISM; HORMONAL REGULATION; HUMAN; MENTAL DISEASE; NEUROBIOLOGY; NEUROENDOCRINOLOGY; NEUROPSYCHIATRY; PRIORITY JOURNAL; SCHIZOPHRENIA;

ALZHEIMER DISEASE; BRAIN; COGNITION; DEPRESSION; ESTROGENS; FEMALE; HUMANS; MENTAL DISORDERS; SCHIZOPHRENIA;

EID: 0038818479     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.74.7.837     Document Type: Editorial

References (54)

1. Writing group for the Women's Health Initiative. Risks and benefits of oestrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321-33.
2. Gould E, Woolley CS, Frankfurt M, et al. Gonadal steroids regulate dendritic spine density in hippocampal pyramidal cells in adulthood. J Neurosci 1990;10:1286-91.
3. Gazzaley AH, Weiland NG, McEwen BS, et al. Differential regulations of NMDAR1 mRNA and protein by estradiol in the rat hippocampus. J Neurosci 1996;16:6830-8.
4. Woolley CS, Weiland NG, McEwen BS, et al. Estradiol increases the sensitivity of hippocampal CA1 pyramidal cells to NMDA receptor-mediated synaptic input: correlation with dendritic spine density. J Neurosci 1997;17:1848-59.
5. McEwen BS, Alves SE, Bulloch K, et al. Ovarian steroids and the brain: implications for cognition and aging. Neurology 1997;48(suppl 7):S8-15.
6. Luine VN, Khylchevskaya RI, McEwen BS. Effect of gonadal steroids on activities of monoamine oxidase and choline acetylase in rat brain. Brain Res 1975;86:293-306.
7. Singh M, Meyer EM, Millard WJ, et al. Ovarian steroid deprivation results in a reversible learning impairment and compromised cholinergic function in female Sprague-Dawley rats. Brain Res 1994;644:305-12.
8. Gibbs RB, Burke AM, Johnson DA. Estrogen replacement attenuates effects of scopolamine and lorazepam on memory acquisition and retention. Hormones Behav 1998;34:112-25.
9. O'Keane V, Dinan TG. Sex steroid priming effects on growth hormone response to pyridostigmine throughout the menstrual cycle. J Clin Endocrinol Metab 1992;75:11-14.
10. Lucey JV, O'Keane V, O'Flynn K, et al. Gender and age differences in the growth hormone response to pyridostigmine. Int Clin Psychopharmacol 1991;6:105-9.
11. Van Amelsvoort T, Murphy DGM, Robertson D, et al. Effects of long-term estrogen replacement therapy on growth hormone response to pyridostigmine in healthy postmenopausal women. Psychoneuroendocrinology 2003;28:101-12.
12. Smith YR, Minoshima S, Kuhl DE, et al. Effects of long-term hormone therapy on cholinergic synaptic concentrations in healthy postmenopausal women. J Clin Endocrinol Metab 2001;86:679-84.
13. Vertes RP. A PHA-L analysis of ascending projections of the dorsal raphe nucleus in the rat. J Comp Neurol 1991;313:643-68.
14. Osterlund MK, Keller E, Hurd YL. The human forebrain has discrete estrogen receptor alpha messenger RNA expression: high levels in the amygdaloid complex. Neuroscience 2000;95:333-42.
15. Hall JM, Couse JF, Korach KS. The multifaceted mechanisms of estradiol and estrogen receptor signaling. J Biol Chem 2001;276:36869-72.
16. Sumner BE, Fink G. The density of 5-hydoxytryptamine2A receptors in forebrain is increased at pro-oestrus in intact female rats. Neurosci Lett 1997;234:7-10.
17. Biegon A, Reches A, Snyder L, et al. Serotonergic and noradrenergic receptors in the rat brain: modulation by chronic exposure to ovarian hormones. Life Sci 1983;32:2015-21.
18. Pecins-Thompson M, Brown NA, Kohama SG, et al. Ovarian steroid regulation of tryptophan hydroxylase mRNA expression in rhesus macaques. J Neurosci 1996;16:7021-9.
19. Moses EL, Drevets WC, Smith G, et al. Effects of estradiol and progesterone administration on human serotonin 2A receptor binding: a PET study. Biol Psychiatry 2000;48:854-60.
20. van Amelsvoort T, Abel KM, Robertson DM, et al. Prolactin response to d-fenfluramine in postmenopausal women on and off ERT: comparison with young women. Psychoneuroendocrinology 2001;26:493-502.
21. Toran-Allerand CD. The estrogen/neurotrophin connection during neural development: is co-localization of estrogen receptor with the neurotrophins and their receptors biologically relevant? Dev Neurosci 1996;18:36.
22. Simpkins JW, Singh M, Bishop J. The potential role for estrogen replacement therapy in the treatment of the cognitive decline and neurodegeneration associated with Alzheimer's disease. Neurobiol Aging 1994;15(suppl 2):S195-7.
23. Xu H, Gouras GK, Greenfield JP, et al. Estrogen reduces neuronal generation of Alzheimer beta-amyloid peptides. Nat Med 1998;4:447-51.
24. Behl C. Oestrogen as a neuroprotective hormone. Nat Rev Neurosci 2002;3:433-42.
25. Sherwin BB. Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women. Psychoneuroendocrinology 1988;13:345-57.
26. Phillips SM, Sherwin BB. Effects of estrogen on memory function in surgically menopausal women. Psychoneuroendocrinology 1992;17:485-95.
27. Hampson E. Variations in sex-related cognitive abilities across the menstrual cycle. Brain Cogn 1990;14:26-43.
28. Maki PM, Resnick SM. Effects of estrogen on patterns of brain activity at rest and during cognitive activity: a review of neuroimaging studies. Neuroimage 2001;14:789-801.
29. Shaywitz SE, Shaywitz BA, Pugh KR, et al. Effect of estrogen on brain activation patterns in postmenopausal women during working memory tasks. JAMA 1999;281:1197-202.
30. Maki PM, Resnick SM. Longitudinal effects of estrogen replacement therapy on PET cerebral blood flow and cognition. Neurobiol Aging 2000;21:373-83.
31. Robertson DM, van Amelsvoort T, Daly E, et al. Effects of estrogen replacement therapy on human brain aging: an in vivo 1H MRS study. Neurology 2001;57:2114-17.
32. Henderson VW, Paganini-Hill A, Emanuel CK, et al. Estrogen replacement therapy in older women: comparisons between Alzheimer's disease cases and nondemented control subjects. Arch Neurol 1994;51:896-900.
33. Tang MX, Jacobs D, Stern Y, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996;348:429-32.
34. Doraiswamy PM, Krishen A, Martin WL, et al. Gender, concurrent estrogen use and cognition in Alzheimer's disease. Int J Geriatr Psychopharmacol 1997;1:34-7.
35. Wang PN, Liao SQ, Liu RS, et al. Effects of estrogen on cognition, mood, and cerebral blood flow in AD: a controlled study. Neurology 2000;54:2061-6.
36. Henderson VW, Paganini-Hill A, Miller BL, et al. Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial. Neurology 2000;54:295-301.
37. Mulnard RA, Cotman CW, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA 2000;283:1007-15.
38. Asthana S, Baker LD, Craft S, et al. High-dose estradiol improves cognition for women with AD: results of a randomized study. Neurology 2001;57:605-12.
39. Mulnard RA, Cotman CW, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. JAMA 2000;283:1007-15.
40. Schneider LS, Farlow MR, Henderson VW, et al. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease. Neurology 1996;46:1580-4.
41. Dluzen DE, McDermott JL, Liu B. Estrogen alters MPTP-induced neurotoxicity in female mice: effects on striatal dopamine concentrations and release. J Neurochem 1996;66:658-66.
42. Hallonquist JD, Seeman MV, Lang M, et al. Variation in symptom severity over the menstrual cycle of schizophrenics. Biol Psychiatry 1993;33:207-9.
43. Lindamer LA, Lohr JB, Harris MJ, et al. Gender, estrogen, and schizophrenia. Psychopharmacol Bull 1997;33:221-8.
44. Riecher-Rossler A, Hafner H, Dutsch-Strobel A, et al. Further evidence for a specific role of estradiol in schizophrenia? Biol Psychiatry 1994;36:492-4.
45. Kulkarni J, Riedel A, de Castella AR, et al. Estrogen - a potential treatment for schizophrenia. Schizophr Res 2001;48:137-44.
46. Epperson CN, Wisner KL, Yamamoto B. Gonadal steroids in the treatment of mood disorders. Psychosom Med 1999;61:676-97.
47. Kumar R, Robson KM. A prospective study of emotional disorders in childbearing women. Br J Psychiatry 1984;144:35-47.
48. Bebbington PE, Dunn G, Jenkins R, et al. The influence of age and sex on the prevalence of depressive conditions: report from the National Survey of Psychiatric Morbidity. Psychol Med 1998;28:9-19.
49. Sichel DA, Cohen LS, Robertson LM, et al. Prophylactic estrogen in recurrent postpartum affective disorder. Biol Psychiatry 1995;38:814-18.
50. Gregoire AJP, Kumar R, Everitt B, et al. Transdermal oestrogen for treatment of severe postnatal depression. Lancet 1996;347:930-3.
51. Klaiber EL, Broverman DM, Vogel W, et al. Estrogen therapy for severe persistent depressions in women. Arch Gen Psychiatry 1979;36:550-4.
52. Schneider LS, Small GW, Hamilton SH, et al. Estrogen replacement and response to fluoxetine in a multicenter geriatric depression trial. Fluoxetine Collaborative Study Group. Am J Geriatr Psychiatry 1997;5:97-106.
53. Schmidt PJ, Nieman L, Danaceau MA, et al. Estrogen replacement in perimenopause-related depression: a preliminary report. Am J Obstet Gynecol 2000;183:414-20.
54. Soares CN, Almeida OP, Joffe H, et al. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 2001;58:529-34.